Palvella Therapeutics (PVLA) & Its Peers Head-To-Head Review

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,068 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Palvella Therapeutics to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, risk, institutional ownership and valuation.

Institutional and Insider Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 6.4% of Palvella Therapeutics shares are held by company insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Palvella Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.56
Palvella Therapeutics Competitors	$9.97 billion	$135.94 million	-7.29

Palvella Therapeutics’ competitors have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for Palvella Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	4	0	3.00
Palvella Therapeutics Competitors	8165	21842	49701	1311	2.55

Palvella Therapeutics presently has a consensus price target of $40.33, suggesting a potential upside of 113.97%. As a group, “Pharmaceutical preparations” companies have a potential upside of 251.00%. Given Palvella Therapeutics’ competitors higher possible upside, analysts plainly believe Palvella Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Palvella Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.82%	-235.83%	-32.89%

Risk & Volatility

Palvella Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ competitors have a beta of 3.66, suggesting that their average stock price is 266% more volatile than the S&P 500.

Summary

Palvella Therapeutics competitors beat Palvella Therapeutics on 8 of the 13 factors compared.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.